Analysts Expect Eli Lilly and Company (NYSE:LLY) to Announce $1.90 Earnings Per Share

Brokerages expect Eli Lilly and Company (NYSE:LLYGet Rating) to report earnings of $1.90 per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Eli Lilly and’s earnings. The lowest EPS estimate is $1.80 and the highest is $2.12. Eli Lilly and reported earnings of $1.87 per share during the same quarter last year, which would indicate a positive year over year growth rate of 1.6%. The company is scheduled to report its next earnings results on Monday, January 1st.

On average, analysts expect that Eli Lilly and will report full-year earnings of $8.34 per share for the current fiscal year, with EPS estimates ranging from $8.15 to $8.80. For the next year, analysts forecast that the company will post earnings of $9.58 per share, with EPS estimates ranging from $9.00 to $9.86. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Eli Lilly and.

Eli Lilly and (NYSE:LLYGet Rating) last released its quarterly earnings results on Thursday, April 28th. The company reported $2.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.30. The firm had revenue of $7.81 billion for the quarter, compared to the consensus estimate of $7.29 billion. Eli Lilly and had a return on equity of 97.58% and a net margin of 20.90%. The company’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter last year, the business posted $1.87 EPS.

LLY has been the topic of a number of research reports. Wells Fargo & Company boosted their price objective on shares of Eli Lilly and from $280.00 to $305.00 in a research report on Friday, April 29th. Morgan Stanley increased their price objective on shares of Eli Lilly and from $364.00 to $369.00 in a research note on Friday, April 29th. SVB Leerink assumed coverage on Eli Lilly and in a research report on Monday, May 23rd. They issued an “outperform” rating and a $341.00 target price on the stock. Daiwa Capital Markets started coverage on Eli Lilly and in a research report on Thursday, March 10th. They set an “outperform” rating and a $286.00 price target for the company. Finally, StockNews.com raised Eli Lilly and from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $304.58.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction dated Friday, March 4th. The shares were sold at an average price of $262.24, for a total transaction of $55,070,400.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Marschall S. Runge bought 202 shares of the company’s stock in a transaction dated Tuesday, March 1st. The stock was purchased at an average price of $246.78 per share, with a total value of $49,849.56. The disclosure for this purchase can be found here. Insiders have sold 1,327,818 shares of company stock worth $380,782,218 over the last ninety days. Insiders own 0.12% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Eli Lilly and by 1.8% in the first quarter. Vanguard Group Inc. now owns 70,481,178 shares of the company’s stock valued at $20,183,695,000 after buying an additional 1,219,424 shares in the last quarter. State Street Corp lifted its holdings in shares of Eli Lilly and by 2.5% in the fourth quarter. State Street Corp now owns 33,929,864 shares of the company’s stock worth $9,372,107,000 after acquiring an additional 813,983 shares during the last quarter. Capital World Investors boosted its stake in shares of Eli Lilly and by 17.0% in the 1st quarter. Capital World Investors now owns 22,358,444 shares of the company’s stock valued at $6,402,838,000 after purchasing an additional 3,242,548 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Eli Lilly and by 2.9% during the 4th quarter. Geode Capital Management LLC now owns 14,731,168 shares of the company’s stock valued at $4,059,130,000 after purchasing an additional 409,009 shares during the last quarter. Finally, Capital International Investors increased its position in Eli Lilly and by 30.5% during the 1st quarter. Capital International Investors now owns 8,839,241 shares of the company’s stock worth $2,532,024,000 after purchasing an additional 2,063,557 shares in the last quarter. 82.75% of the stock is currently owned by institutional investors and hedge funds.

NYSE LLY opened at $323.48 on Friday. Eli Lilly and has a 52 week low of $196.68 and a 52 week high of $324.08. The company has a debt-to-equity ratio of 1.60, a quick ratio of 0.98 and a current ratio of 1.27. The stock’s 50 day moving average price is $295.16 and its two-hundred day moving average price is $269.47. The stock has a market capitalization of $307.36 billion, a price-to-earnings ratio of 47.92, a PEG ratio of 2.27 and a beta of 0.40.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 10th. Shareholders of record on Monday, May 16th will be issued a $0.98 dividend. This represents a $3.92 dividend on an annualized basis and a yield of 1.21%. The ex-dividend date of this dividend is Friday, May 13th. Eli Lilly and’s dividend payout ratio is currently 58.07%.

About Eli Lilly and (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Read More

Get a free copy of the Zacks research report on Eli Lilly and (LLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Want More Great Investing Ideas?

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.